Odyssey Therapeutics, Inc.(ODTX)
$19.36+0.22 (+1.15%)
ODTX
Odyssey Therapeutics, Inc. financials statements
$19.36
At close:+0.22 (+1.15%)
Odyssey Therapeutics, Inc. (ODTX) Ratios
14 Followers
Odyssey Therapeutics, Inc. Ratios
ODTX's free cash flow for Q3 2026 was $-42.05M. For the 2026 fiscal year, ODTX's free cash flow was decreased by $-504.00K and operating cash flow was $-41.54M. See a summary of the company’s cash flow.
| Ratios | Dec 25 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 7.20 |
| Quick Ratio | 7.20 |
| Cash Ratio | 1.57 |
| Solvency Ratio | -0.19 |
| Operating Cash Flow Ratio | -4.89 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Net Current Asset Value | $ -567.41M |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.10 |
| Debt-to-Equity Ratio | -0.06 |
| Debt-to-Capital Ratio | -0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | -0.55 |
| Debt Service Coverage Ratio | -8454.06 |
| Interest Coverage Ratio | -9479.76 |
| Debt to Market Cap | 0.00 |
| Interest Debt Per Share | 0.58 |
| Net Debt to EBITDA | 0.10 |
| Profitability Margins | |
| Gross Profit Margin | 100.00% |
| EBIT Margin | -5025.44% |
| EBITDA Margin | -4860.42% |
| Operating Profit Margin | -5415.19% |
| Pretax Profit Margin | -5026.01% |
| Net Profit Margin | -4994.86% |
| Continuous Operations Profit Margin | -4994.86% |
| Net Income Per EBT | 99.38% |
| EBT Per EBIT | 92.81% |
| Return on Assets (ROA) | -55.10% |
| Return on Equity (ROE) | 30.44% |
| Return on Capital Employed (ROCE) | -66.23% |
| Return on Invested Capital (ROIC) | -64.44% |
| Return on Tangible Assets | -58.25% |
| Earnings Yield | -19.19% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 0.00 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.11 |
| Asset Turnover | 0.01 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | 0.00 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 0.00 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -2.74 |
| Free Cash Flow Per Share | -2.77 |
| Dividend Paid and CapEx Coverage Ratio | -105.09 |
| Capital Expenditure Coverage Ratio | -105.09 |
| Operating Cash Flow Coverage Ratio | -4.78 |
| Operating Cash Flow to Sales Ratio | -43.50 |
| Free Cash Flow Yield | -16.87% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -5.21 |
| Price-to-Sales (P/S) Ratio | 260.28 |
| Price-to-Book (P/B) Ratio | -1.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.93 |
| Price-to-Operating Cash Flow Ratio | -5.98 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 |
| Enterprise Value Multiple | -5.25 |
| Enterprise Value | 760.02M |
| EV to EBITDA | -5.25 |
| EV to Sales | 255.38 |
| EV to Free Cash Flow | -5.82 |
| EV to Operating Cash Flow | -5.87 |
| Tangible Book Value Per Share | -10.66 |
| Shareholders’ Equity Per Share | -10.35 |
| Tax and Other Ratios | |
| Effective Tax Rate | 0.01 |
| Revenue Per Share | 0.06 |
| Net Income Per Share | -3.15 |
| Tax Burden | 0.99 |
| Interest Burden | 1.00 |
| Research & Development to Revenue | 42.55 |
| SG&A to Revenue | 12.61 |
| Stock-Based Compensation to Revenue | 4.81 |
| Income Quality | 0.87 |
Currency in USD

